NGM Biopharmaceuticals, Inc. (NGM)
| Market Cap | 1.97B |
| Revenue (ttm) | 98.68M |
| Net Income (ttm) | -90.44M |
| Shares Out | 68.82M |
| EPS (ttm) | -1.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $26.52 |
| Previous Close | $27.94 |
| Change ($) | -1.42 |
| Change (%) | -5.08% |
| Day's Open | 28.04 |
| Day's Range | 26.00 - 28.60 |
| Day's Volume | 337,571 |
| 52-Week Range | 10.00 - 31.44 |
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...
– Event to showcase NGM's multi-therapeutic area p ipeline , including its oncology por tfolio and Geographic Atrophy and NASH programs –
--Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intrao...
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...
NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative th...
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative ...
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative ...
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -15.15% and -3.25%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the...
--Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer-- --Aldafermin continues to advance toward late-stage clinical developmen...
NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate NGM Biopharmaceuticals (NGM) to Report a Decline in Earnings: What to Look Out for
NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative ...
-- Multicenter, randomized, double-masked, sham-controlled study will evaluate safety and efficacy of intravitreal injections of NGM621 every four or eight weeks for 48 weeks -- -- GA is a pr...
NGM Biopharmaceuticals (NGM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for ...
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.45% and 22.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the ...
-- Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis) -- -- Continuing enr...
SOUTH SAN FRANCISCO, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that, due to public health and safety concerns related to the coronav...
Market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns.
NGM Biopharmaceuticals Inc (NASDAQ: NGM), which went public about a year back, has seen its shares trade mostly below the IPO price of $16.
SOUTH SAN FRANCISCO, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for pati...
Strong results on multiple measures put the company's drug candidate firmly in the NASH discussion.
Shares popped after the clinical-stage biotech reported upbeat clinical results.
NGM Biopharmaceuticals Inc (NASDAQ: NGM) is advancing strongly on above-average volume Monday following a positive clinical data readout.
--Study to evaluate potential of GDF15/GFRAL pathway inhibition to block tumor-associated weight loss and tumor growth-- --CACS, an uncontrolled wasting syndrome, is a common co-morbidity of ...
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therape...
As of late, it has definitely been a great time to be an investor NGM Biopharmaceuticals.
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
NGM Biopharmaceuticals announces positive data from Phase 2b study treating patients with NASH using NGM282.
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therape...
Tough industry conditions and company-specific issues hit these stocks.
About NGM
NGM Biopharmaceuticals, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the tr... [Read more...]
| Industry Biotechnology | IPO Date Apr 4, 2019 |
| CEO David Woodhouse | Employees 186 |
| Stock Exchange NASDAQ | Ticker Symbol NGM |
Analyst Forecasts
According to 9 analysts, the average rating for NGM stock is "Strong Buy." The 12-month stock price forecast is 37.78, which is an increase of 42.46% from the latest price.